New Drug Slashes Dangerous Blood Fats by Nearly 40% in First Human Trial

Scientists have found a way to fine-tune a central fat-control pathway in the liver, reducing harmful blood triglycerides while preserving beneficial cholesterol functions.

When we eat, the body turns surplus calories into molecules called "triglycerides", especially when those calories come from carbs, sugar, fats, and alcohol. Triglycerides are a type of fat or "lipid", and the body stores them in fat cells to use as fuel between meals.

However, too much of this fat can become harmful. High triglyceride levels can lead to "hypertriglyceridemia" ("excess triglycerides in the blood"), a condition tied to a much higher risk of heart disease, stroke, and pancreatitis. That is why people are widely encouraged to support healthy triglyceride levels through diet and exercise, while more severe cases may require medication.

Dialing down a receptor

Healthy blood fat levels rely on a balance between how much fat enters circulation and how quickly it is removed. The liver and intestine send fat carrying particles into the bloodstream, and enzymes help break them down so the body can clear them. If the body produces more of these fats than it can process, triglycerides accumulate and can contribute to disorders such as dyslipidemia, acute pancreatitis, and metabolic dysfunction-associated steatotic liver disease (MASLD).

A key regulator in this network is the Liver X Receptor, or LXR, a protein that controls multiple genes involved in how the body produces and manages fats.

When LXR activity increases, triglycerides and cholesterol often climb as well. Reducing LXR signaling with a drug could be useful, but there is a catch. Because LXR also supports protective cholesterol related pathways in other tissues, shutting it down throughout the body could create unwanted effects. This tradeoff has made it difficult to turn LXR into a safe treatment target.

A drug that specifically targets liver LXR

Researchers led by Johan Auwerx at EPFL and Mani Subramanian at OrsoBio have now developed an orally administered compound designed to curb LXR activity mainly in the liver and gut. The goal is to lower triglycerides while leaving the body's protective cholesterol pathways intact.

The drug, TLC-2716, is described as an "inverse agonist" for LXR. Unlike a "blocker" ("antagonist") that simply prevents activation, an "inverse agonist" pushes the receptor toward the reverse of its usual signaling.

The work, published in Nature Medicine, is the first study of this approach to be tested in humans.

Combing genetic datasets to find the right receptor variant

The scientists began by analyzing large human genetics datasets to determine which LXR variant is related to biomarkers for elevated triglycerides in the blood. The data pointed to the genetic variants within LXRα, which is highly expressed in the liver.

This was further confirmed through "Mendelian randomization", a powerful method that determines causal relationships between gene expression and outcomes. In this case, it confirmed a causal link between LXRα and metabolic disorders: higher LXRα expression can drive triglycerides upward.

The findings helped select TLC‑2716 as an effective compound to test against LXRα.

Testing the compound

The study then moved from computers into the lab. In rodent models of metabolic disease, TLC‑2716 and a related compound lowered triglycerides and cholesterol in the blood and reduced fat accumulation in the liver. Meanwhile, experiments in human liver organoids (miniature lab-grown models of diseased liver tissue), showed the same trend, with less lipid buildup and lower inflammation and fibrosis.

Next was safety. Toxicology studies in mice and non-human primates, combined with pharmacokinetic analyses, showed that TLC‑2716 largely stays in the liver and gut. This is key, as it limits exposure to other tissues where inhibiting LXR could be risky, thus addressing the main problem of developing drugs for treating metabolic diseases related to high triglycerides in the body.

The clinical trial

The lab findings set the stage for a randomized, placebo-controlled Phase 1 study in healthy adults. Participants received TLC‑2716 for 14 days, given as a single dose per day, and the trial focused first on safety and tolerability, and the authors report that the drug met these primary endpoints.

But even this short trial had clear effects: participants who received higher doses of TLC‑2716 showed notable drops in triglycerides as well as remnant cholesterol. At the highest doses of TLC‑2716 (12mg), triglycerides fell by up to 38.5%, while postprandial ("after eating") remnant cholesterol dropped by as much as 61%. This happened despite participants starting with relatively normal lipid levels and without the use of other lipid-lowering drugs.

The treatment also sped up triglyceride clearance by reducing the activity of two proteins that normally slow it down, ApoC3 and ANGPTL3. At the same time, the study did not detect reductions in blood-cell expression of ABCA1 and ABCG1, genes used here as markers linked to reverse cholesterol transport.

The trial's results show that selectively reducing LXR activity in the liver and gut by TLC‑2716 may offer a new way, complementary to other approaches, to tackle high triglycerides and related metabolic disorders. The Phase 1 data support further clinical testing in Phase 2 studies, including in people with hypertriglyceridemia and MASLD. Larger trials will be needed, but, for now, the concept has its first human proof of principle.

Reference: "An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial" by Xiaoxu Li, Giorgia Benegiamo, Archana Vijayakumar, Natalie Sroda, Masaki Kimura, Ryan S. Huss, Steve Weng, Eisuke Murakami, Brian J. Kirby, Giacomo V. G. von Alvensleben, Claus Kremoser, Edward J. Gane, Takanori Takebe, Robert P. Myers, G. Mani Subramanian and Johan Auwerx, 16 January 2026, Nature Medicine.
DOI: 10.1038/s41591-025-04169-6

Funding: École Polytechnique Fédérale de Lausanne (EPFL), NIH/National Institutes of Health, Japan Agency for Medical Research and Development, Japan World Premier International Research Center Initiative (WPI), OrsoBio